Terms: = Lung cancer AND TNFRSF14, Q92956, 8764, ENSG00000157873, TR2, ATAR, LIGHTR, HVEM, HVEA AND Treatment
3 results:
1. Anti-hvem mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human hvem and BTLA molecules challenged with hvem expressing tumors.
Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
[TBL] [Abstract] [Full Text] [Related]
2. Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell lung cancer.
Wang Q; He Y; Li W; Xu X; Hu Q; Bian Z; Xu A; Tu H; Wu M; Wu X
Front Immunol; 2022; 13():887916. PubMed ID: 35874720
[TBL] [Abstract] [Full Text] [Related]
3. The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands.
de Ruiter JC; Heineman DJ; Daniels JM; van Diessen JN; Damhuis RA; Hartemink KJ
Lung Cancer; 2020 Jun; 144():64-70. PubMed ID: 32371262
[TBL] [Abstract] [Full Text] [Related]
